Workflow
ASC50
icon
Search documents
歌礼制药-B再涨超7% 公司拟斥最多3亿港元进行股份购回 机构称下半年催化剂较多
Zhi Tong Cai Jing· 2025-10-08 06:48
消息面上,歌礼制药公布,董事会已决定行使购回授权,并根据市况不时于公开市场购回股份,以使用 最多3亿港元的资金进行建议股份购回。东吴证券此前指出,公司下半年催化剂较多,多个重要临床数 据即将披露:根据临床试验进度和公司公告,该行预计2025年Q4将读出ASC30口服II期、ASC47的I期 及ASC50的I期顶线数据,2026年Q1将读出ASC30皮下注射II期顶线数据。同时公司预计未来6-9个月将 向FDA申报2-3个新管线的IND,包含双靶点多肽减重管线。 歌礼制药-B(01672)再涨超7%,截至发稿,涨6.8%,报11.62港元,成交额5646.13万港元。 ...
港股异动 | 歌礼制药-B(01672)再涨超7% 公司拟斥最多3亿港元进行股份购回 机构称下半年催化剂较多
智通财经网· 2025-10-08 06:47
消息面上,歌礼制药公布,董事会已决定行使购回授权,并根据市况不时于公开市场购回股份,以使用 最多3亿港元的资金进行建议股份购回。东吴证券此前指出,公司下半年催化剂较多,多个重要临床数 据即将披露:根据临床试验进度和公司公告,该行预计2025年Q4将读出ASC30口服II期、ASC47的I期 及ASC50的I期顶线数据,2026年Q1将读出ASC30皮下注射II期顶线数据。同时公司预计未来6-9个月将 向FDA申报2-3个新管线的IND,包含双靶点多肽减重管线。 智通财经APP获悉,歌礼制药-B(01672)再涨超7%,截至发稿,涨6.8%,报11.62港元,成交额5646.13万 港元。 ...
歌礼制药-B涨超5% ASC30展现优越疗效及安全性数据 公司下半年催化剂较多
Zhi Tong Cai Jing· 2025-09-17 07:06
Core Viewpoint - The stock of Gilead Sciences-B (01672) increased by over 5%, currently trading at 10.88 HKD with a transaction volume of 92.59 million HKD, following the announcement of positive results from its ASC30 oral GLP-1R agonist study [1] Group 1: Clinical Trial Results - Gilead announced that at the 61st European Association for the Study of Diabetes (EASD) conference in Vienna, it reported results from its ASC30 oral GLP-1R agonist 28-day multiple dose escalation study [1] - The ASC30 oral tablet showed an average weight loss of up to 6.5% after 28 days of treatment, adjusted for placebo [1] - The efficacy of ASC30 is attributed to its higher oral drug exposure, with good safety and tolerability, experiencing only mild to moderate gastrointestinal adverse events [1] Group 2: Future Catalysts - Dongwu Securities noted that Gilead has several catalysts in the second half of the year, with multiple important clinical data expected to be disclosed [1] - The firm anticipates that by Q4 2025, Gilead will read out phase II topline data for ASC30 oral, phase I data for ASC47, and phase I data for ASC50, with phase II topline data for ASC30 subcutaneous expected in Q1 2026 [1] - The company plans to submit 2-3 new IND applications to the FDA for its pipeline, including a dual-target peptide weight loss program, within the next 6-9 months [1]
歌礼制药-B午后涨超4% 临床数据显示超长半衰期 ASC30有望推出季度制剂
Zhi Tong Cai Jing· 2025-09-15 06:35
Core Viewpoint - The stock of Gilead Sciences-B (01672) rose over 4% following the announcement of promising clinical data for its long-acting GLP-1R agonist ASC30, indicating potential for quarterly dosing in weight management [1] Group 1: Clinical Developments - Gilead announced that its small molecule GLP-1R agonist ASC30 has shown a 75-day apparent half-life in obese subjects, suggesting a long-term weight management solution [1] - The ASC30 formulation is developed using Gilead's Ultra Long-Acting Drug Development Platform (ULAP) [1] Group 2: Shareholder Commitments - Gilead's controlling shareholder has made a voluntary lock-up commitment, agreeing not to sell any shares before the release of three key clinical data points [1] - The three data points include: 1. Topline data from the U.S. Phase I clinical study of ASC47 combined with semaglutide, expected by the end of September 2025 [1] 2. Topline data from the U.S. 13-week Phase IIa clinical study of ASC30 oral tablets in overweight or obese subjects, expected by December 2025 [1] 3. Topline data from the U.S. Phase I single ascending dose study of ASC50 in healthy subjects, expected by December 2025 [1]
港股异动 | 歌礼制药-B(01672)早盘涨超5% 控股股东作出自愿禁售承诺 ASC30有望推出季度制剂
智通财经网· 2025-09-12 02:13
Core Viewpoint - The stock of Gilead Sciences-B (01672) rose over 5% in early trading, driven by the announcement of a voluntary lock-up commitment from the controlling shareholder, which will prevent the sale of shares until key clinical data is released [1] Group 1: Clinical Trials and Data - Gilead Sciences announced that the controlling shareholder will not sell any company shares before the release of three key clinical data points: 1. Top-line data from the U.S. Phase I clinical trial of ASC47 combined with semaglutide in obese subjects, expected by the end of September 2025 2. Top-line data from the U.S. 13-week Phase IIa clinical trial of ASC30 oral tablets in obese or overweight subjects, expected by December 2025 3. Top-line data from the U.S. Phase I single ascending dose study of ASC50 in healthy subjects, expected by December 2025 [1][1][1] Group 2: Drug Development and Potential - The company recently announced that the small molecule GLP-1R agonist ASC30 demonstrated an apparent half-life of 75 days in obese subjects, indicating the potential for developing a long-term weight management solution with quarterly dosing [1][1] - ASC30 is developed using Gilead's Ultra-Long-Acting Drug Development Platform (ULAP), and the company has multiple pipelines relying on this platform to develop long-acting formulations, which may meet various clinical needs [1][1]
歌礼制药-B获控股股东作出自愿禁售承诺
Zhi Tong Cai Jing· 2025-09-11 23:56
Core Viewpoint - The announcement from the company reflects a strong commitment to its long-term value and future prospects, as demonstrated by the voluntary shareholding commitment from key executives [1] Group 1: Shareholder Commitment - Dr. Wu Jinzi and He Jingdao have voluntarily committed not to sell or pledge any shares they control until the release of three key clinical trial data points [1] - The three clinical data readouts include: (i) top-line data from the U.S. Phase I clinical study of ASC47 combined with semaglutide, expected by the end of September 2025; (ii) top-line data from the U.S. 13-week Phase IIa clinical study of ASC30 oral tablets in overweight or obese subjects, expected by December 2025; and (iii) top-line data from the U.S. Phase I single ascending dose study of ASC50 in healthy subjects, also expected by December 2025 [1] - As of the announcement date, the total number of voluntarily locked-up shares held by Dr. Wu and his wife amounts to 576 million shares, representing approximately 58.03% of the company's existing issued share capital (excluding treasury shares) [1]
歌礼制药-B(01672)获控股股东作出自愿禁售承诺
智通财经网· 2025-09-11 23:56
Core Viewpoint - The company expresses strong confidence in its long-term value and future prospects through a voluntary commitment by its founder and major shareholders to not sell any shares before the release of three key clinical trial data points [1] Group 1: Clinical Trial Data Commitments - The founder, Dr. Wu, and his spouse, Ms. He, have committed not to sell or pledge any shares they control until the following clinical data readouts: 1. Topline data from the U.S. Phase I clinical study of ASC47 combined with Semaglutide in obese subjects, expected by the end of September 2025 2. Topline data from the U.S. 13-week Phase IIa clinical study of ASC30 oral tablets in obese or overweight subjects, expected by the end of December 2025 3. Topline data from the U.S. Phase I single ascending dose study of ASC50 in healthy subjects, expected by the end of December 2025 [1][1][1] Group 2: Shareholding Information - As of the announcement date, Dr. Wu and Ms. He hold a total of 576 million shares, representing approximately 58.03% of the company's existing issued share capital (excluding treasury shares) [1][1][1]
歌礼制药-B(01672.HK)控股股东作出自愿禁售承诺 押注三大临床研究结果
Ge Long Hui· 2025-09-11 23:39
Core Viewpoint - The company, Gilead Sciences-B (01672.HK), has announced a voluntary commitment by its founder and major shareholders to not sell any shares before the release of three key clinical trial data points, reflecting their confidence in the company's long-term value and future prospects [1] Group 1: Shareholder Commitment - Dr. Wu Jinzi and Ms. He Jingdao have committed to not selling or pledging any shares they control until the release of three specific clinical trial results [1] - The three clinical data readouts include: (i) top-line data from the U.S. Phase I clinical study of ASC47 combined with semaglutide in obese subjects, expected by the end of September 2025; (ii) top-line data from the U.S. 13-week Phase IIa clinical study of ASC30 oral tablets in obese or overweight subjects, expected by the end of December 2025; and (iii) top-line data from the U.S. Phase I single ascending dose study of ASC50 in healthy subjects, also expected by the end of December 2025 [1] - As of the announcement date, the total number of voluntarily locked-up shares held by Dr. Wu and Ms. He is approximately 576 million shares, representing about 58.03% of the company's existing issued share capital (excluding treasury shares) [1]
歌礼制药(01672) - 自愿性公告 - 控股股东作出自愿禁售承诺
2025-09-11 23:30
香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責,對其準確性 或完整性亦不發表任何聲明,並明確表示,概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 本公告乃歌禮製藥有限公司(「本公司」或「歌禮」,連同其附屬公司稱為「本集 團」)自願作出。 本公司董事(「董事」)會(「董事會」)謹此宣布,其獲告知,為表達對本公司長遠 價值及未來前景的堅定信心,吳勁梓博士(歌禮創始人、董事會主席兼首席執行 官、及本公司控股股東,「吳博士」),與何淨島(本公司執行董事及控股股東、吳 博士之配偶,「吳夫人」)一起,已自願承諾在如下3個臨床數據讀出前,不會出 售(包括但不限於出售或質押)任何由彼等或彼等各自控制的實體直接或間接實益 擁有的本公司股份(「股份」):(i) ASC47聯合司美格魯肽在肥胖受試者中進行的 美國I期臨床研究頂線數據,預計於2025年9月底獲得;(ii) ASC30口服片在肥胖 或超重受試者中進行的美國13周IIa期臨床研究頂線數據,預計於2025年12月獲 得;及(iii) ASC50在健康受試者中進行的美國I期單劑量遞增研究頂線數據,預 計於202 ...
东吴证券:维持歌礼制药-B(01672)“买入”评级 ASC30有望推出季度制剂
智通财经网· 2025-09-10 06:32
ASC30注射剂半衰期喜人,季度制剂成为可能 东吴证券主要观点如下: 在此前的Ib期临床中,ASC30用于减重维持的超长效皮下储库型(depot)制剂的单次100mg皮下注射在肥 胖受试者(BMI ≥ 30 kg/m2)中显示出75天的表观半衰期,100mg单次注射后再17天达到血药峰浓度。长 期体重管理仍然是一个重大未满足的临床需求,更长效的季度给药方案将为患者提供一种在达到目标体 重后的维持体重方案。 安全性数据优秀,耐受性支持长期用药 智通财经APP获悉,东吴证券发布研报称,歌礼制药-B(01672)2025年各项管线推进顺利,符合该行预 期。未来临床数据披露时间相对明确。该行认为其未来成功上市可能性较高。该行维持25-27年营收预 测0.02/0.64/2.03亿元,维持"买入"评级。9月9日,公司发布公告称小分子GLP-1R激动剂ASC30用于减 重维持的超长效皮下储库型制剂在肥胖受试者中显示出75天的表观半衰期。这意味着ASC30未来有望开 发出具有季度给药周期的长期体重管理维持方案。 ASC30减重维持制剂利用歌礼超长效药物开发平台(Ultra-Long-Acting Platform,ULAP ...